Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Knight to Present at Stifel GMP's The Future of Healthcare Conference

12/02/2021 | 07:56pm EST

MONTREAL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the upcoming Stifel GMP Future of Healthcare Conference on Wednesday, December 8, 2021 at 10 am ET, that will be held virtually. A live webcast of the event will be available at the following link: Event. A copy of the presentation will be available at www.gud-knight.com.

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Investor Contact: 
Knight Therapeutics Inc. 
  
Samira SakhiaArvind Utchanah
President & Chief Executive OfficerChief Financial Officer
T: 514.484.4483T. 514.484.4483
F: 514.481.4116F. 514.481.4116
Email: info@knighttx.comEmail: info@knighttx.com
Website: www.gud-knight.comWebsite: www.gud-knight.com

All news about KNIGHT THERAPEUTICS INC.
01/06Knight Therapeutics Announces Approval of Breast Cancer Drug, Halaven, in Colombia
MT
01/06KNIGHT THERAPEUTICS BRIEF : Announces Approval of Halaven in Colombia
MT
01/06Knight Therapeutics Inc. Announces Approval of Halaven« in Colombia
AQ
01/06Knight Therapeutics Inc. Announces Approval of Halaven« in Colombia
CI
01/05Knight Therapeutics Inc. Announces Approval of Lenvima in Colombia
AQ
01/04Knight Therapeutics Reports Approval of Lenvima in Colombia
MT
01/04Knight Therapeutics Inc. Announces Approval of Lenvima« in Colombia
AQ
01/04Knight Therapeutics Inc. Announces Approval of Lenvima« in Colombia
CI
2021Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
2021Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
More news
Financials
Sales 2021 247 M 196 M 196 M
Net income 2021 22,8 M 18,1 M 18,1 M
Net Debt 2021 - - -
P/E ratio 2021 26,6x
Yield 2021 -
Capitalization 627 M 500 M 498 M
Capi. / Sales 2021 2,54x
Capi. / Sales 2022 2,17x
Nbr of Employees 679
Free-Float 80,1%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 5,32 CAD
Average target price 7,80 CAD
Spread / Average Target 46,6%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
James Charles Gale Lead Independent Director
Robert N. Lande Independent Director
Sector and Competitors